Skip to main content

Table 2 Factors associated with reported adverse events in 228 exposed HCWs/HCSs on HIV post-exposure prophylaxis

From: Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana

Characteristic Adverse events status1 Crude hazard ratio [95 % CI] p-value Adjusted hazard ratio [95 % CI] p-value
Present Absent
Drug regimen       
3TC/AZT −28 days 68 7 1.00   1.00  
3TC/AZT-3 days 28 73 0.31 [0.20–0.48] <0.001 0.30 [0.18–0.48] <0.001
3TC/AZT/LPV-RTV-28 days 50 2 1.06 [0.74–1.53] 0.752 1.06 [0.65–1.72] 0.817
Gender       -
Female 81 50 1.00    
Male 65 32 1.08 [0.78–1.50] 0.629   
Type of exposure       -
Percutaneous 131 80 1.00    
Mucocutaneous 15 2 1.42 [0.83–2.43] 0.197   
Age category (yrs)       -
18–30 101 60 1.00    
31–40 32 18 1.02 [0.69–1.52] 0.921   
41–50 8 2 1.28 [0.62–2.62] 0.508   
>51 5 2 1.14 [0.46–2.80] 0.777   
Risk assessment       
Low 51 63 1.00   1.00  
Medium 40 16 1.60 [1.06–2.42] 0.027 0.95 [0.61–1.49] 0.885
High 55 3 2.12 [1.45–3.10] <0.001 0.97 [0.57–1.66] 0.922
Profession       -
Nurses 51 31 1.00    
HCS 14 10 0.94 [0.52–1.69] 0.832   
Laboratory Staff 15 1 1.51 [0.85–2.68] 0.162   
Medical Doctors 46 31 0.96 [0.65–1.43] 0.843   
Ward Attendants 20 9 1.11 [0.66–1.86] 0.695   
  1. 1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval